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Introduction {#sec006}
============

Network meta-analysis (NMA) is increasingly accepted as a valuable methodology by clinical researchers and health care decision makers.\[[@pone.0121715.ref001]--[@pone.0121715.ref003]\] Network meta-analysis has been described as the "new generation" of evidence synthesis and the number of published studies is growing rapidly.\[[@pone.0121715.ref004]\] The approach has been embraced by national health technology assessment agencies in a number of countries, including Australia, Canada, and the UK.\[[@pone.0121715.ref005]--[@pone.0121715.ref007]\] The Cochrane Collaboration has also introduced a new type of review called 'Overviews of Reviews', which summarize the relative effectiveness of multiple competing interventions for a single indication.\[[@pone.0121715.ref008],[@pone.0121715.ref009]\] A report by the Agency for Healthcare Research and Quality in the US identified 25 publicly-available guidance documents on how to conduct and report network meta-analyses.\[[@pone.0121715.ref010]\] National and regional health technology assessment agencies prepared the majority of these documents, although the guidance issued by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) was considered to be most comprehensive.\[[@pone.0121715.ref010]\]

The objective of this study was to assess the methodological quality of published NMAs. Previous studies have documented the growth and study characteristics of the NMA literature through July 2012.\[[@pone.0121715.ref003],[@pone.0121715.ref004],[@pone.0121715.ref011]--[@pone.0121715.ref014]\] These reviews investigated the validity assumptions and methods of using NMAs. Our study builds on this body of literature in several ways. First, we update the evidence by including articles published up to July 2014. Second, we investigate the methods, the transparency and reproducibility, and the presentation of findings in these studies. Finally, we compare the characteristics of studies published in journals with lower impact factors with those published in journals with higher impact factors, studies published prior to January 1^st^, 2013 with those published after that date, and studies supported financially by industry with those supported by non-profit or that received no support.

Methods {#sec007}
=======

We systematically searched for all published network meta-analyses in the Ovid-MEDLINE database using the following search terms: *network meta-analysis; indirect treatment comparison; mixed treatment comparison*; and, *multiple treatments meta-analysis*. The date of our last search was July 30^th^, 2014. We limited our search to studies including randomized controlled trials with human participants; we only included articles published in English-language journals. We excluded NMAs submitted to national health technology assessment agencies unless they were subsequently published in the medical literature.

Two trained reviewers reviewed each abstract independently using predefined inclusion criteria. We only included NMAs with at least one pharmaceutical in the set of treatments examined and data from at least three clinical trials; we also only included NMAs that compared the efficacy of the treatments. We excluded methodological studies, cost-effectiveness studies, editorials, and letters to the editor. Two trained reviewers independently extracted data from each included study; the reviewers resolved disagreements through consensus. We reviewed all published material related to each NMA, including the online supplementary material and appendices. When the source of study funding was undeclared or unclear, we contacted the corresponding author for the information.

Using a standardized data collection form, we collected information for each NMA on general study characteristics, study methods, transparency, and presentation of findings. We reported the following study characteristics: journal name; study authors; publication year; study support (industry or other); journal impact factor (as reported on Journal Citation Reports)\[[@pone.0121715.ref015]\]; country (determined by the corresponding author's affiliation); number of included active treatments; number of clinical trials included; total number of patients included; and indication and patient population studied. We also noted all of the comparator treatments, including non-pharmaceutical treatments and different modes of administration of the same pharmaceutical.

We applied objective assessment criteria from the "checklist of good research practices" in the ISPOR guidance for interpreting and conducting indirect-treatment-comparison and network-meta-analysis studies.\[[@pone.0121715.ref016],[@pone.0121715.ref017]\] Our assessment criteria included the following: Study method assessment criteria Was a Bayesian or a frequentist framework used?Was the risk of bias of included clinical trials assessed? (e.g., using the Cochrane Collaboration\'s tool for assessing risk of bias or the Jadad scale?) \[[@pone.0121715.ref018],[@pone.0121715.ref019]\]Did the analysis include adjustments for model covariates?Was a fixed or random effects model used? Or, were the findings of both fixed and random effects models presented?Was an assessment of model fit reported?Was a sensitivity analysis performed? (e.g., varied the included clinical studies to evaluate the robustness of the findings)For studies with at least one closed loop, was the consistency of direct evidence and indirect evidence evaluated? (i.e., presented and compared the findings from the traditional meta-analysis and the network meta-analysis)Study transparency and reproducibility assessment criteria Were the search terms reported?Was a network diagram of included treatments presented?Was data from the included clinical studies necessary to reproduce the network meta-analysis presented?Was a table of key clinical study characteristics presented?Was the model code presented or source cited? (reported for studies performed using a Bayesian framework only)Presentation of study findings Were pairwise comparisons of all included treatments presented?Was the probability of each treatment being best reported? (reported for studies performed using a Bayesian framework only)Was a ranking of treatments in terms of effectiveness reported? (reported for studies performed using a Bayesian framework only)

To compare studies published in high- and low-impact journals, we evenly split the sample based on the reported journal impact factors (cut-off point: impact factor above and below 3.534). To compare older and newer studies, we again divided the sample in two (cut-off point: published before and after January 1^st^, 2013). We used our categorization of study support to compare industry-supported studies with studies with and non-industry-supported studies. We used a Chi-square test and a student's t-test to evaluate categorical and continuous variables, respectively. We considered p-values below the 5% level as statistically significant. Analyses were undertaken using Stata 13.

Results {#sec008}
=======

Our systematic literature search identified 854 citations. We reviewed the full texts of 386 abstracts met the inclusion criteria. Based on the full text reviews, we excluded another 68 studies. We included 318 studies in our final sample ([Fig 1](#pone.0121715.g001){ref-type="fig"}).

![Identification of network meta-analyses included in review.](pone.0121715.g001){#pone.0121715.g001}

[Table 1](#pone.0121715.t001){ref-type="table"} presents the frequency of published NMAs by year, indication, and country; it also presents the types of included pharmaceutical included. The number of NMAs has increased rapidly each year; about 68% and 48% of studies were published after January 2012 and January 2013, respectively. Studies have evaluated treatments for a range of indications, most commonly those affecting the circulatory (n = 64, 20%) and musculoskeletal systems (n = 45, 14%). Analyses were most often performed by researchers based in the USA (n = 81, 26%), UK (n = 79, 25%), and Canada (n = 28, 9%). The majority of studies adopted a Bayesian framework (n = 214, 67%) and either received non-profit or no support (n = 215, 68%).

10.1371/journal.pone.0121715.t001

###### Frequency of network meta-analyses (n = 210) by year, indication, and country.

![](pone.0121715.t001){#pone.0121715.t001g}

  Year study published[^†^](#t001fn001){ref-type="table-fn"}                                             n
  ------------------------------------------------------------------------------------------------------ -------------
  1997                                                                                                   1 (0.3%)
  2003                                                                                                   3 (0.9%)
  2004                                                                                                   1 (0.3%)
  2006                                                                                                   3 (0.9%)
  2007                                                                                                   3 (0.9%)
  2008                                                                                                   9 (2.8%)
  2009                                                                                                   16 (5.0%)
  2010                                                                                                   21 (6.9%)
  2011                                                                                                   44 (13.8%)
  2012                                                                                                   66 (20.4%)
  2013                                                                                                   43 (24.5%)
  2014 (through July 31st)                                                                               73 (23.0%)
  **International Statistical Classification of Diseases (ICD) disease categories**                      **n**
  Blood Disease                                                                                          3 (0.9%)
  Circulatory System                                                                                     64 (20.1%)
  Digestive System                                                                                       13 (4.1%)
  Endocrine, Nutritional, Metabolic, and Immunity                                                        28 (8.8%)
  Genitourinary System                                                                                   7 (2.2%)
  Infectious and Parasite Disease                                                                        14 (4.4%)
  Mental and Behavioral Disorder                                                                         13 (4.1%)
  Musculoskeletal System and Connective Tissue                                                           45 (14.2%)
  Neoplasm                                                                                               39 (12.3%)
  Nervous System and Sensory Organs                                                                      33 (10.4%)
  Respiratory System                                                                                     20 (6.3%)
  Skin and Subcutaneous Tissues                                                                          9 (2.8%)
  Other                                                                                                  30 (9.4%)
  **Country**                                                                                            **n**
  USA                                                                                                    81 (25.5%)
  UK                                                                                                     79 (24.8%)
  Canada                                                                                                 28 (8.8%)
  Italy                                                                                                  21 (6.6%)
  China                                                                                                  16 (5.0%)
  France                                                                                                 14 (4.4%)
  The Netherlands                                                                                        10 (3.1%)
  Germany                                                                                                8 (2.5%)
  Brazil                                                                                                 6 (1.9%)
  Switzerland                                                                                            6 (1.9%)
  Taiwan                                                                                                 6 (1.9%)
  Greece                                                                                                 5 (1.6%)
  Spain                                                                                                  4 (1.3%)
  Other                                                                                                  34 (10.7%)
  **Type of pharmaceutical intervention included**                                                       **n**
  Multiple pharmaceuticals compared                                                                      304 (95.6%)
  Study included a non pharmaceutical treatment (e.g., surgery, exercise, counselling, etc)              30 (9.4%)
  Different strengths of the same pharmaceutical compared (e.g., simvastatin 20mg vs. 40mg)              82 (25.8%)
  Treatments in the same drug class grouped together as a comparator (e.g., beta-blockers, or statins)   75 (23.6%)
  Multiple modes of administration of a drug compared (e.g., oral, sublingual, intramuscular, etc)       10 (3.1%)

^†^ We limited our literature search to studies published in the medical literature. We did not include NMAs submitted to national health technology assessment agencies unless also published in the Ovid-MEDLINE database.

\* 'Other countries' includes Greece, Ireland, Singapore, Australia, Cameroon, Denmark, Finland, Hong Kong, Korea, Norway, Poland, and Portugal.

The vast majority of network meta-analyses compared multiple pharmaceuticals (n = 304, 96%), while a minority included a non-pharmaceutical comparator treatment (n = 30, 9%). Some researchers grouped treatments in the same therapeutic class, e.g., beta-blockers or statins, as a single comparator treatment (n = 75, 24%). Different dosages, e.g., simvastatin 20 mg vs. 40 mg, were compared in 82 (26%) studies, and ten studies (3%) compared different modes of administration of the same pharmaceutical, e.g., oral vs. intramuscular injection.

We found many differences among the included studies ([Table 2](#pone.0121715.t002){ref-type="table"}). In terms of study methods, 30% of studies did not perform a risk of bias assessment of included studies, 60% did not report an assessment of model fit, and 44% did not include a sensitivity analysis. Among studies with a closed loop, i.e., three or more included treatments had been compared in head-to-head trials, 40% did not report the consistency of direct and indirect evidence. In terms of study transparency and reproducibility, 20% did not report the systematic review search terms, 39% did not present a network diagram, 35% did not present sufficient data from contributing studies to replicate the analysis, and 10% did not provide details of the key characteristics of included trials. Thirty-six percent of included studies did not present the full matrix of head-to-head treatment comparisons. For studies performed using a Bayesian framework, 41% reported the probability that each included treatment was best, 31% reported a ranking of included treatments, and 16% included or directed readers to the model code.

10.1371/journal.pone.0121715.t002

###### Assessment of network meta-analysis study characteristics.

![](pone.0121715.t002){#pone.0121715.t002g}

                                                                                                                                                         Journal quality (n = 301)[\*](#t002fn002){ref-type="table-fn"}   Date of study publication (n = 318)   Source of study support (n = 315)[\*\*](#t002fn003){ref-type="table-fn"}                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------- ---------------- ---------------------------------------------------------------- ------------------------------------- -------------------------------------------------------------------------- ---------------- ---------------- ------------ ---------------- ---------------- --------------
  ***General study characteristics***                                                                                                                                                                                                                                                                                                                                                                                       
  Number of treatments compared                                                                                                         6.3 (±6.4)       6.8 (±8.5)                                                       6.0 (±3.9)                            0.3136                                                                     6.0 (±4.2)       6.7 (±8.2)       0.3816       5.9 (±3.6)       6.5 (±7.3)       0.446
  Total number of studies                                                                                                               32.9 (±45.5)     28.3 (±38.6)                                                     36.5 (±46.9)                          0.0992                                                                     30.5 (±50.2)     35.5 (±50.2)     0.3341       22.7 (±29.4)     37.4 (±50.5)     **0.0079**
  Total number of patients                                                                                                              26875 (±65936)   21938 (±46061)                                                   33292 (±82859)                        0.1549                                                                     23711 (±49899)   30460 (±80375)   0.3732       10945 (±13183)   33864 (±77635)   **0.005**
  HTA region (UK, AUS and Canada)[^†^](#t002fn001){ref-type="table-fn"}                                                                 110 (35%)        50 (34%)                                                         56 (36%)                              0.6709                                                                     68 (47%)         42 (28%)         **0.0156**   48 (49%)         62 (28%)         **0.0003**
  Journal impact factor                                                                                                                 5.5 (±6.2)       NA                                                               NA                                    NA                                                                         5.8 (±6.5)       5.2 (±5.9)       0.3791       3.1 (±1.7)       6.5 (±7.1)       **\<0.0001**
  ***Study method***                                                                                                                                                                                                                                                                                                                                                                                                        
  Bayesian framework                                                                                                                    214 (67%)        91 (62%)                                                         109 (71%)                             0.1038                                                                     106 (63%)        108 (72%)        0.1273       75 (77%)         139 (63%)        **0.0191**
  Risk of bias assessment of included studies                                                                                           223 (70%)        100 (68%)                                                        111 (72%)                             0.4446                                                                     103 (62%)        120 (79%)        **0.0005**   53 (54%)         170 (77%)        **\<0.0001**
  Adjustment for covariates                                                                                                             92 (29%)         35 (24%)                                                         51 (33%)                              0.0744                                                                     54 (32%)         38 (25%)         0.1601       37 (38%)         55 (25%)         **0.0205**
  Random effects model[\*\*\*](#t002fn004){ref-type="table-fn"}                                                                         221 (70%)        98 (67%)                                                         114 (75%)                             0.1609                                                                     116 (69%)        106 (71%)        0.7453       67 (68%)         155 (71%)        0.6243
  Assessment of model fit                                                                                                               127 (40%)        53 (36%)                                                         70 (45%)                              0.0979                                                                     69 (41%)         58 (38%)         0.5985       46 (47%)         81 (37%)         0.0894
  Sensitivity analysis                                                                                                                  179 (56%)        73 (50%)                                                         96 (62%)                              **0.0267**                                                                 88 (53%)         91 (60%)         0.1752       57 (58%)         122 (58%)        0.6542
  Consistency of direct and indirect evidence reported[\*\*\*\*](#t002fn005){ref-type="table-fn"} (closed loop studies only, n = 167)   116 (69%)        39 (57%)                                                         73 (79%)                              **0.0017**                                                                 57 (66%)         59 (73%)         0.3606       16 (39%)         100 (79%)        **\<0.0001**
  ***Study transparency and reproducibility***                                                                                                                                                                                                                                                                                                                                                                              
  Search terms reported                                                                                                                 254 (80%)        112 (76%)                                                        129 (84%)                             0.1007                                                                     129 (77%)        125 (83%)        0.2201       61 (62%)         193 (88%)        **\<0.0001**
  Network diagram                                                                                                                       194 (61%)        85 (58%)                                                         101 (66%)                             0.1671                                                                     103 (62%)        91 (60%)         0.7974       62 (63%)         132 (60%)        0.5829
  Extracted data from contributing clinical studies                                                                                     206 (65%)        87 (60%)                                                         106 (69%)                             0.0955                                                                     116 (69%)        91 (61%)         0.1011       58 (60%)         149 (68%)        0.1726
  Table of key clinical study characteristics                                                                                           286 (90%)        128 (87%)                                                        141 (92%)                             0.2084                                                                     145 (87%)        141 (93%)        0.0527       89 (91%)         197 (90%)        0.729
  Model code (Bayesian framework only, n = 214)                                                                                         35 (16%)         9 (6%)                                                           24 (16%)                              **0.0085**                                                                 24 (14%)         11 (7%)          **0.0439**   8 (8%)           27 (12%)         0.2811
  ***Presentation of study findings***                                                                                                                                                                                                                                                                                                                                                                                      
  Full matrix of head-to-head comparisons                                                                                               203 (64%)        84 (57%)                                                         108 (70%)                             **0.0191**                                                                 110 (66%)        93 (62%)         0.4294       44 (45%)         159 (73%)        **\<0.0001**
  Reported probability of being best (Bayesian framework only, n = 214)                                                                 87 (41%)         32 (22%)                                                         51 (33%)                              **0.0277**                                                                 41 (25%)         46 (30%)         0.2389       25 (26%)         62 (28%)         0.623
  Ranking of included treatments (Bayesian framework only, n = 214)                                                                     67 (31%)         26 (18%)                                                         40 (26%)                              0.0829                                                                     29 (17%)         39 (26%)         0.0664       11 (11%)         56 (26%)         **0.0031**

^†^ Regions in which submissions to HTA agencies generally require a NMA;

\* 17 studies published in journals with no associated impact factor;

\*\* 3 studies for which source of study support was unclear;

\*\*\* 77 studies reported both fixed and random effects models, 38 studies did not report models used;

\*\*\*\* Consistency only reported for studies with a closed loop

Journal quality {#sec009}
---------------

We found that NMAs published in journals with higher impact factors more often performed a sensitivity analysis (62% versus 50%, p = 0.0267) and reported the full matrix of head-to-head comparisons (70% versus 57%, p = 0.0191). For studies with a closed loop, those published in journals with higher impact factors more often compared the consistency of direct and indirect evidence (79% versus 57%, p = 0.0017). For studies performed using a Bayesian framework, studies published in higher impact factor journals more often reported the probability of each treatment being best (33% versus 22%, p = 0.0277), and the model code (16% versus 6%, p = 0.0085).

Publication date {#sec010}
----------------

We found that studies published prior to January 1^st^, 2013 were more often authored by researchers based in regions where HTA agencies include NMAs in their assessments (47% versus 28%, p = 0.0156). Studies published prior to January 1^st^, 2013 less often performed a risk of bias assessment of included trials (62% versus 79%, p = 0.005), but, for Bayesian studies, more often reported the model code or cited publicly-available code (14% versus 7%, p = 0.0439).

Source of financial support {#sec011}
---------------------------

We found a number of differences between industry-supported studies and non-industry supported studies. Industry-supported studies included fewer trials (22.7 versus 37.4, p = 0.0079) and a smaller total number of patients (10945 versus 33864, p = 0.0050). A greater proportion of industry-funded studies were authored by researchers based in regions in which HTA agencies often include NMA in their assessments (49% versus 28%, p = 0.0079). Industry-supported studies were on average published in journals with lower impact factors (3.1 versus 6.5, p\<0.0001).

Industry-supported studies more often used a Bayesian framework (77% versus 63%, p = 0.0191), and adjusted for study covariates (38% versus 25%, p = 0.0251); however, they less often performed a risk of bias assessment of included studies (54% versus 77%, p\<0.0001), and, for Bayesian studies, less often compared the consistency of direct and indirect evidence (39% versus 79%, p\<0.0001).

Industry-supported studies less often reported the search terms used in the systematic literature review (62% versus 88%, p\<0.0001), and reported the full matrix of head-to-head comparisons (45% versus 73%, p\<0.0001). For studies performed using a Bayesian framework, industry-supported studies less often reported a ranking of treatments (11% versus 26%, p = 0.0031).

Discussion {#sec012}
==========

Network meta-analyses are increasingly recognized as offering valuable information to the medical community. Growth in the NMA literature has been rapid, with roughly half of studies in our dataset published since January 1^st^, 2013. Our dataset includes studies by researchers based in 30 countries, confirming NMAs as a global research enterprise. We found notable variation across published network meta-analyses with respect to methods, transparency and reproducibility, and presentation of findings.

As expected, we found that studies published in higher-impact journals performed better across our assessment criteria, suggesting that higher-quality journals publish higher quality NMAs. Our findings may also point to a marginal improvement in the conduct and reporting of NMAs over time, with more recently published studies more often performing a risk of bias assessment of included trials. Interestingly, more recent Bayesian studies less often reported the model code, perhaps reflecting the fact that example model code has become easily accessible and freely available.\[[@pone.0121715.ref020]\] It is notable that a smaller proportion of studies are now authored by researchers based in regions where HTA agencies include network meta-analysis in their assessments. This likely reflects the widespread acceptance of NMA and the growing international use of the technique by researchers.

We also found differences among NMAs according to source of financial support. For instance, we found that industry-supported studies tended to be published in journals with a lower impact factor. Similarly, industry-supported studies were more often authored by researchers based in HTA regions, which is likely due to the publication of NMAs that were previously included in a submission to a regulatory agency. An interesting finding is that industry-sponsored studies less often used a Bayesian framework, the reason for which is unclear.

Consistent with the studies published in journals with higher impact factors, we found that industry-supported studies less often reported the full matrix of head-to-head comparisons. For NMAs with a closed loop, they less often compared the consistency of direct and indirect evidence. Like older analyses, industry-supported studies were less likely to perform a risk of bias assessment of included trials.

Other identified differences between industry-supported and non-industry-supported studies do not appear to be explained by journal quality or the data of publication. For instance, industry-supported studies included fewer contributing trials and total patients, and less often reported the systematic review search terms. Industry sponsored Bayesian network meta-analyses less often reported a ranking of included drugs based on efficacy, although they more often adjusted for covariates. However, as we emphasize below, these findings should be interpreted with caution due to limitations of our assessment criteria.

Study limitations {#sec013}
-----------------

While our assessment criteria were based on published guidelines for the conduct and reporting of network meta-analysis, they may have been insufficient to fully assess study quality. For example, while we determined whether a study reported a sensitivity analysis or assessed the model fit, we did not judge whether the approaches were appropriate or sufficient. We also did not evaluate whether the set of included treatments was appropriate or comprehensive. This is a salient consideration as the inappropriate inclusion or exclusion of treatments can significantly affect study findings.

Furthermore, a study may have not met an assessment criterion, or appear to have performed poorly on a given criterion, for good reason. For instance, while industry-supported studies included fewer contributing studies and total patients, this may reflect the precision of the study research question, rather than the how comprehensively the question was addressed. Similarly, while guidelines recommend assessing included trials for risk of bias, the influence of individual design components of individual randomized trials on the findings is variable. \[[@pone.0121715.ref021]--[@pone.0121715.ref023]\] While it is recommended that the consistency between direct and indirect evidence should be assessed, researchers may be more inclined to do so when there is apparent heterogeneity among the included trials.\[[@pone.0121715.ref024]--[@pone.0121715.ref028]\]

For indications for which the relative efficacy of existing treatments has been established by multiple NMAs, a researcher may choose to compare a newly-introduced treatment to existing interventions, rather than to report the full matrix. Moreover, it is reported that treatment rankings may at times be an unreliable metric for comparative efficacy and safety, and authors may choose not to present these findings.\[[@pone.0121715.ref029]\]

Our comparison of NMAs on the basis of study support has a number of additional limitations. First, while we took great care when categorizing studies as 'industry-supported' and contacted authors when source of support was ambiguous, we predominantly relied on the reported disclosures. Second, we did not compare the conclusions of industry-and non-industry-supported NMAs. To determine if industry-supported studies tend to produce more favourable conclusions about the study sponsors' drugs, it would be necessary to identify and compare industry sponsored and non-industry sponsored trials that evaluate the same clinical research questions.\[[@pone.0121715.ref030],[@pone.0121715.ref031]\] Unfortunately, while various NMAs have been conducted for some indications, these studies often considered different research questions and included different treatments. This prevented us from evaluating the NMA literature in this way.

Moving forward {#sec014}
--------------

This research highlights the need for greater consistency in the conduct and reporting of NMAs. In addition to the ISPOR recommendations used here, there exist a multitude of guidelines and recommendations with notable differences. This suggests that a consensus, on which NMA methods are most appropriate has not been reached.\[[@pone.0121715.ref010]\] \[[@pone.0121715.ref032]\] While the development of guidelines advances the field, inconsistencies between guidelines may impede standardization. For example, while all guidelines are unanimous in stating the consistency between direct and indirect evidence should be assessed, there is disagreement with respect to the importance of testing model fit, the use of fixed- or random-effects models, and the exclusion or inclusion of covariates in the model.\[[@pone.0121715.ref010]\]

As NMAs are an extension of traditional meta-analyses, it seems logical that they should be held to similar methodological and reporting standards. For systematic reviews and traditional meta-analysis, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol---which consists of a 27-item checklist and a four-phase flow diagram---has emerged as the standard reporting approach.\[[@pone.0121715.ref033]\] The forthcoming extension of the PRISMA guidelines for network meta-analysis may consolidate existing recommendations, and serve as the authoritative guideline.

Still, our study underscores that checklists should be considered only as guides to study quality. A NMA that satisfies all criteria on a given checklist may not necessarily be a high-quality study, and a study that does not meet various criteria may not necessarily be a low-quality study. Indeed, the recent ISPOR-AMCP-NPC Good Practice Task Force Report is a questionnaire, not a checklist, reflecting the challenge of creating a 'one size fits all' checklist for network meta-analyses.\[[@pone.0121715.ref034]\] It is important that users of network meta-analyses critique the research, and make their own judgment regarding study quality and accuracy. Journal editors should ensure that published network meta-analyses are transparent and reproducible, and that these studies present findings in an unambiguous and comprehensive manner.
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